IQMD

NASDAQ

Intelligent Medicine Acquisition Corp.

SectorIndustrialsIndustryConsumer Electronics/AppliancesIPO2021

News25/Ratings0

Intelligent Medicine Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to identify business opportunities in the field of life science. The company was incorporated in 2021 and is based in Bethesda, Maryland.

Latest news

25 items

799d13D/G
SEC Form SC 13G filed by Intelligent Medicine Acquisition Corp.
SC 13G - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)
1077dSEC
SEC Form 15-12G filed by Intelligent Medicine Acquisition Corp.
15-12G - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1087dSEC
SEC Form 25-NSE filed by Intelligent Medicine Acquisition Corp.
25-NSE - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)
1092dINSIDER
SEC Form 3: New insider Goldman Sachs Group Inc claimed ownership of 200,000 shares
3 - Intelligent Medicine Acquisition Corp. (0001850051) (Issuer)
1093dSEC
Intelligent Medicine Acquisition Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
8-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1093dNEWS
Intelligent Medicine Acquisition Corp. Announces It Will Redeem Its Public Shares
1093dPR
Intelligent Medicine Acquisition Corp. Announces It Will Redeem Its Public Shares
Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD) (the "Company"), a blank-check company formed for the purpose of acquiring or merging with one or more businesses, today announced that because the Company does not believe it will be able to consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation (the "Charter"), the Company intends to dissolve and liquidate in accordance with the provisions of the Charter, and will redeem all of the outstanding shares of Class A common stock that were included in the units issued in its initial public offering (the "Public Shares"), at a per-share redemption price of approximate
1102dSEC
SEC Form 10-K filed by Intelligent Medicine Acquisition Corp.
10-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1106d13D/G
SEC Form SC 13G/A filed by Intelligent Medicine Acquisition Corp. (Amendment)
SC 13G/A - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)
1112dSEC
Intelligent Medicine Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
8-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1114dSEC
Intelligent Medicine Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
8-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1116dSEC
SEC Form NT 10-K filed by Intelligent Medicine Acquisition Corp.
NT 10-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1150dINSIDER
SEC Form 4: Saba Capital Management, L.P. returned $22,443,808 worth of shares to the company (2,170,581 units at $10.34)
4 - Intelligent Medicine Acquisition Corp. (0001850051) (Issuer)
1157d13D/G
SEC Form SC 13D filed by Intelligent Medicine Acquisition Corp.
SC 13D - Intelligent Medicine Acquisition Corp. (0001850051) (Subject)
1168dINSIDER
SEC Form 4 filed by Intelligent Medicine Sponsor Llc
4 - Intelligent Medicine Acquisition Corp. (0001850051) (Issuer)
1169dSEC
Intelligent Medicine Acquisition Corp. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
8-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1175dSEC
SEC Form DEFA14A filed by Intelligent Medicine Acquisition Corp.
DEFA14A - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1175dSEC
Intelligent Medicine Acquisition Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
8-K - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1175dPR
Intelligent Medicine Acquisition Corp. Announces Adjournment of Special Meeting of Stockholders
Intelligent Medicine Acquisition Corp. (NASDAQ:IQMD) (the "Company") announced today that it has postponed the Company's Special Meeting of Stockholders to be held on February 3, 2023, at 9:30 a.m. Eastern Time until February 8, 2023, at 9:30 a.m. Eastern Time. The postponed Special Meeting will be completely virtual, and stockholders will be able to attend the special meeting online, vote and submit questions by visiting https://www.cstproxy.com/iqmdspac/2023. There will be no change in the record date as a result of this postponement or the date by which stockholders must have elected to redeem their public shares, and proxies tendered prior to the postponed date will not need to be voted
1182dSEC
SEC Form DEFA14A filed by Intelligent Medicine Acquisition Corp.
DEFA14A - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1190dSEC
SEC Form DEF 14A filed by Intelligent Medicine Acquisition Corp.
DEF 14A - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1205dSEC
SEC Form PRE 14A filed by Intelligent Medicine Acquisition Corp.
PRE 14A - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1256dSEC
SEC Form 10-Q filed by Intelligent Medicine Acquisition Corp.
10-Q - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1347dSEC
SEC Form 10-Q filed by Intelligent Medicine Acquisition Corp.
10-Q - Intelligent Medicine Acquisition Corp. (0001850051) (Filer)
1409dPR
Kroll Appoints Patience Marime-Ball as Senior Advisor to Kroll's ESG Advisory Services
Kroll, the leading provider of data, technology and insights related to risk, governance and growth, announced today Patience Marime-Ball will be a Senior Advisor to Kroll's Environmental, Social and Governance (ESG) Advisory Services Committee. Kroll provides an extensive range of advisory support and technology solutions to address growing ESG challenges, create sustainable value and growth, and effectively manage risk. Marime-Ball will play a critical role advising Kroll and its clients on how to drive meaningful changes that will help benefit people and the planet. "We're excited to welcome Patience as a new Senior Advisor to Kroll on ESG," said Jake Silverman, Chief Executive Officer